Identification of key pathways and biomarkers in sorafenib-resistant hepatocellular carcinoma using bioinformatics analysis

Hepatocellular carcinoma (HCC) is one of the most common malignant types of cancer, with a high mortality rate. Sorafenib is the sole approved oral clinical therapy against advanced HCC. However, individual patients exhibit varying responses to sorafenib and the development of sorafenib resistance h...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Danping, Yuan, Weiqu, Li, Hanmin, Li, Shaodong, Chen, Zuanguang, Yang, Hongzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122189/
https://www.ncbi.nlm.nih.gov/pubmed/30186410
http://dx.doi.org/10.3892/etm.2018.6427

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122189/
https://www.ncbi.nlm.nih.gov/pubmed/30186410
http://dx.doi.org/10.3892/etm.2018.6427

Ejemplares similares